Most bothersome sites are the face and legs. If the disease starts early, it has a greater severity. Vitiligo is seen more frequent in children with atopic dermatitis [2]. Ezzedine et al. (2014) identify 2 clinical subtypes of vitiligo: those with early onset disease (<12 years) are characterised by a family history of vitiligo, a family history of premature greying, and halo nevi; those with late onset disease (>12 years) often have acrofacial localisation [3]. Research has shown that cosmetic camouflage leads to a significant improvement in quality of life in children with vitiligo [4].
Compared with adults, comorbidity with regard to autoimmune disease is lower in children, but multiple studies have documented an increased frequency of thyroid disorders [5-7]. “I strongly recommend that you get a thyroid panel if this is the only lab you do,” said Prof. Grimes. In children, there is a higher incidence of segmental vitiligo (see Figure). “Treatment goal is to stabilise and improve quality of life. Fortunately, excellent therapeutic outcomes are often achieved in children,” said Prof. Grimes. To treat vitiligo successfully, a multi-modality approach is warranted: It is important to decrease the oxidative stress and the aberrant immune response, and to stimulate melanocyte regrowth and proliferation. Oral corticosteroids (prednisone 5-10 mg daily) are necessary to stabilise vitiligo. Narrowband UVB phototherapy is an effective method to stimulate repigmentation: in a retrospective study, a repigmentation rate of >75% was achieved in 45.4% of cases [8]. In general, children show enhanced repigmentation compared with adult patients. In addition, “vitamin D is a powerful antioxidant and is often deficient in patients with vitiligo, especially when they get older. Therefore, we should also always check vitamin D levels in our patients,” recommended Prof. Grimes.
Figure: Distribution of the clinical types of vitiligo differs between children and adults [1]
Figure kindly provided by Dr Grimes.
1. Grimes PE. Session S002, AAD Annual Meeting, 1-5 March 2019, Washington DC, USA.
2. Ezzedine K et al. Br J Dermatol 2012;167:490-5.
3. Ezzedine K et al. Pigment Cell Melanoma Res 2014:27:134-9.
4. Salsberg JM et al. J Cutan Med Surg 2016;20:211-5.
5. Kartal D et al. Postepy Dermatol Alergol 2016;33:232-234
6. Kroon MW et al. Horm Res Paediatr 2013;79:137-44.
7. Afar T, Isleten F. Indian J Endocrinol Metab 2013:17:1096-9.
8. Yazici S et al. Turk J Med Sci 2017;47:381-4.
Posted on
Previous Article
« Can JAK inhibitors close the current therapeutic gap in AD? Next Article
Hair Loss: No Reason for Therapeutic Nihilism »
« Can JAK inhibitors close the current therapeutic gap in AD? Next Article
Hair Loss: No Reason for Therapeutic Nihilism »
Table of Contents: AAD 2019
Featured articles
Letter from the Editor
Interview with AAD president Prof. George J. Hruza
Late-Breakers
Secukinumab maintains improvements in psoriasis through 5 years of treatment
Bermekimab – a future treatment for atopic dermatitis?
JAK1/2 inhibitor effective in alopecia areata
Novel anti-IgE drug enables durable urticaria control
Dual IL-17A and IL-17F blocker leads to unprecedented response rates in psoriasis
Thicker AK lesions benefit from laser pretreatment with high channel density
New standardised cantharidin product against molluscum contagiosum efficacious in two phase 3 trials
Bruton’s tyrosine kinase inhibitor highly effective in pemphigus vulgaris
Serlopitant reduces pruritus associated with psoriasis
Atopic Dermatitis: Many New Therapies in the Pipeline
New and emerging atopic dermatitis therapies
Food triggers eczema – an imperturbable belief of patients
Psoriasis and Biologics: The Beat Goes On
Psoriasis and Biologics: The Beat Goes On
JAK Inhibitors: A New Frontier in Dermatology
JAK inhibitors: a new therapeutic tool for dermatologists
JAK inhibitors: a pathogenesis-directed therapy for alopecia areata
Can JAK inhibitors close the current therapeutic gap in AD?
Hair Loss: No Reason for Therapeutic Nihilism
Hair Loss: No Reason for Therapeutic Nihilism
Vitiligo: The Beginning of a New Era
Vitiligo in children
Surgical treatment for selected vitiligo cases
JAK-inhibitors: an emerging treatment option for vitiligo
What's New and Hot in Acne
Should we use more hormonal therapy?
Pearls of the Posters
Pemphigus patients prone to osteoporosis
Intralesional 5-fluorouracil induced high clearance rates in cutaneous squamous cell carcinoma
Related Articles
November 19, 2021
Durable intracranial responses with nivolumab/ipilimumab
December 20, 2018
Melanoma incidence continues to rise in Europe
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com